Chemed Corp (CHE) stock analysis

On Oct 15, 2026, our model rated Chemed Corp (CHE) WEAK BUY with 18% confidence at a price of $515.44. That means the signals lean positive, but they are mixed, so conviction is low.

Technical picture

The 14-day RSI is 53, close to the neutral 50 line, so momentum is balanced.

MACD is above its signal line, a sign that short-term momentum is turning up.

The price has slipped below its 50-day moving average but is still above the 200-day: a pullback inside a longer-term uptrend.

Volume is about normal (0.9x the 20-day average).

Trend structure and money flow

Market structure shows a bullish break of structure (BOS): price broke a recent swing high in the direction of the trend, which usually signals trend continuation.

The most recent swing high is $479.49 and the swing low is $364.23; traders often treat these as resistance and support.

Price is sitting in a bearish order block, a zone where large sellers stepped in before, so upside may stall here.

Fundamentals

The PEG ratio is 1.87, which looks reasonably priced for its growth.

The company reports a profit margin of 10.6% and revenue growth of +8.8%.

In its latest quarter it earned $6.06 per share, which beat the $5.60 analysts expected.

The next earnings report is expected around Oct 27, 2026; prices often move sharply around earnings.

Trade plan from the model

The model's long / bullish plan uses an entry near $515.44, a target of $530.05 (+2.8%) and a stop-loss at $494.37 (-4.1%).

That is a reward-to-risk ratio of about 0.7 to 1: the potential loss is bigger than the gain, a weak setup.

The plan has a time limit: reassess by Oct 25, 2026 whatever the price does.

Research notes

The model's one-paragraph read

Leans BUY — composite score +0.18 (WEAK BUY). Technicals: RSI 53.14, MACD bullish, price below SMA50. Fundamentals: PEG 1.87, margin 10.6%, revenue growth 8.8%. Financial results: last EPS surprise +8.2%, next earnings 2026-10-27. Smart Money Concepts: BOS bullish (trend continuation), price retesting a bearish order block. FinGPT news read: positive. Internet research: Chemed (CHE) bulls point to a recent earnings and revenue beat, continued Roto-Rooter franchise-territory buybacks that bring revenue in-house, and expectations for strong earnings growth; UBS’s September initiation with a $650 target is a major recent catalyst. The bear case is relatively modest historical growth—about 4.1% five-year sales CAGR—alongside a 3.9-percentage-point decline in adjusted operating margin and a valuation near 19.4× forward earnings. Sentiment remains mixed: the broader analyst consensus is Hold, with five of seven analysts neutral and an average target of $554.60 versus a reported share price around $513. Suggested levels: entry $515.44, target $530.05, stop-loss $494.37, exit by 2026-10-25 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).

Past ratings for CHE

"Move since" compares each call's price with the latest analysed price.

Recent news on CHE

Search all news on CHE →

Frequently asked questions

Is CHE a buy right now?

As of Oct 15, 2026, our automated model rates Chemed Corp (CHE) WEAK BUY with 18% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.

What is the price target for CHE?

The model's most recent plan targets $530.05 with a stop-loss at $494.37, from an entry near $515.44.

When does Chemed Corp report earnings next?

The next earnings report is expected around Oct 27, 2026.

What does a WEAK BUY rating mean?

A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.